Ménétrier disease (MD) is a rare acquired disorder with an unknown origin. Despite its benign nature, it seems to increase the risk of gastric cancer. MD consists of giant rugal folds that involve the fundus and the body of the stomach with antral sparing, foveolar hyperplasia, and markedly decreased oxyntic glands.1Coffey R. Washington M. Corless C. et al.Ménétrier disease and GIST: hyperproliferative disorders of the stomach.J Clin Invest. 2007; 117: 70-80Crossref PubMed Scopus (96) Google Scholar, 2Rich A. Toro T.Z. Tanksley J. et al.Distinguishing Ménétrier’s disease form its mimics.Gut. 2010; 59: 1617-1624Crossref PubMed Scopus (59) Google Scholar Different names are used to describe it, all related to its clinicopathologic characteristics: giant hypertrophic gastritis, focal foveolar hyperplasia, giant fold gastropathy, hyperplastic hypersecretory gastropathy, hypoalbuminemic hyperplastic gastropathy, and hypertrophic protein-losing gastropathy.2Rich A. Toro T.Z. Tanksley J. et al.Distinguishing Ménétrier’s disease form its mimics.Gut. 2010; 59: 1617-1624Crossref PubMed Scopus (59) Google Scholar MD can present with many nonspecific symptoms such as abdominal pain, nausea, vomiting, peripheral edema secondary to protein loss, low albumin levels, normal gastrin levels, hypochlorhydria, and bleeding features.1Coffey R. Washington M. Corless C. et al.Ménétrier disease and GIST: hyperproliferative disorders of the stomach.J Clin Invest. 2007; 117: 70-80Crossref PubMed Scopus (96) Google Scholar, 2Rich A. Toro T.Z. Tanksley J. et al.Distinguishing Ménétrier’s disease form its mimics.Gut. 2010; 59: 1617-1624Crossref PubMed Scopus (59) Google Scholar Many treatments have been reported to provide therapeutic benefits: corticoids, nonsteroidal anti-inflammatory drugs, antibiotics, anticholinergic agents, H2-receptor antagonists, somatostatin analogues, proton pump inhibitors, H pylori eradication, and monoclonal antibody against the epidermal growth factor receptor. However, each treatment has yielded inconsistent benefits. The only definitive treatment is gastrectomy, but it often is left to refractory cases or when there is a life-threatening risk.2Rich A. Toro T.Z. Tanksley J. et al.Distinguishing Ménétrier’s disease form its mimics.Gut. 2010; 59: 1617-1624Crossref PubMed Scopus (59) Google Scholar, 3Settle S. Washington K. Lind C. et al.Chronic treatment of MD with Erbitux: clinical efficacy and insight into pathophysiology.Clin Gastroenterol Hepatol. 2005; 3: 654-659Abstract Full Text Full Text PDF PubMed Scopus (38) Google ScholarThe differential diagnosis of large gastric folds includes mucosa-associated lymphoid tissue-lymphoma, infiltrative disorders (amyloidosis, granulomatous diseases), polyposis gastric syndromes, enterochromaffin cell hyperplasia, and Zollinger–Ellison disease.2Rich A. Toro T.Z. Tanksley J. et al.Distinguishing Ménétrier’s disease form its mimics.Gut. 2010; 59: 1617-1624Crossref PubMed Scopus (59) Google Scholar The clinical, analytic, radiologic, and pathologic characteristics allow the distinction of all those different clinical entities. Ménétrier disease (MD) is a rare acquired disorder with an unknown origin. Despite its benign nature, it seems to increase the risk of gastric cancer. MD consists of giant rugal folds that involve the fundus and the body of the stomach with antral sparing, foveolar hyperplasia, and markedly decreased oxyntic glands.1Coffey R. Washington M. Corless C. et al.Ménétrier disease and GIST: hyperproliferative disorders of the stomach.J Clin Invest. 2007; 117: 70-80Crossref PubMed Scopus (96) Google Scholar, 2Rich A. Toro T.Z. Tanksley J. et al.Distinguishing Ménétrier’s disease form its mimics.Gut. 2010; 59: 1617-1624Crossref PubMed Scopus (59) Google Scholar Different names are used to describe it, all related to its clinicopathologic characteristics: giant hypertrophic gastritis, focal foveolar hyperplasia, giant fold gastropathy, hyperplastic hypersecretory gastropathy, hypoalbuminemic hyperplastic gastropathy, and hypertrophic protein-losing gastropathy.2Rich A. Toro T.Z. Tanksley J. et al.Distinguishing Ménétrier’s disease form its mimics.Gut. 2010; 59: 1617-1624Crossref PubMed Scopus (59) Google Scholar MD can present with many nonspecific symptoms such as abdominal pain, nausea, vomiting, peripheral edema secondary to protein loss, low albumin levels, normal gastrin levels, hypochlorhydria, and bleeding features.1Coffey R. Washington M. Corless C. et al.Ménétrier disease and GIST: hyperproliferative disorders of the stomach.J Clin Invest. 2007; 117: 70-80Crossref PubMed Scopus (96) Google Scholar, 2Rich A. Toro T.Z. Tanksley J. et al.Distinguishing Ménétrier’s disease form its mimics.Gut. 2010; 59: 1617-1624Crossref PubMed Scopus (59) Google Scholar Many treatments have been reported to provide therapeutic benefits: corticoids, nonsteroidal anti-inflammatory drugs, antibiotics, anticholinergic agents, H2-receptor antagonists, somatostatin analogues, proton pump inhibitors, H pylori eradication, and monoclonal antibody against the epidermal growth factor receptor. However, each treatment has yielded inconsistent benefits. The only definitive treatment is gastrectomy, but it often is left to refractory cases or when there is a life-threatening risk.2Rich A. Toro T.Z. Tanksley J. et al.Distinguishing Ménétrier’s disease form its mimics.Gut. 2010; 59: 1617-1624Crossref PubMed Scopus (59) Google Scholar, 3Settle S. Washington K. Lind C. et al.Chronic treatment of MD with Erbitux: clinical efficacy and insight into pathophysiology.Clin Gastroenterol Hepatol. 2005; 3: 654-659Abstract Full Text Full Text PDF PubMed Scopus (38) Google Scholar The differential diagnosis of large gastric folds includes mucosa-associated lymphoid tissue-lymphoma, infiltrative disorders (amyloidosis, granulomatous diseases), polyposis gastric syndromes, enterochromaffin cell hyperplasia, and Zollinger–Ellison disease.2Rich A. Toro T.Z. Tanksley J. et al.Distinguishing Ménétrier’s disease form its mimics.Gut. 2010; 59: 1617-1624Crossref PubMed Scopus (59) Google Scholar The clinical, analytic, radiologic, and pathologic characteristics allow the distinction of all those different clinical entities.